Sudhakar Pipavath
Overview
Explore the profile of Sudhakar Pipavath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wood D, Kazerooni E, Aberle D, Argento C, Baines J, Boer B, et al.
J Natl Compr Canc Netw
. 2025 Jan;
23(1.
PMID: 39819601
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening provide criteria for selecting individuals for screening and offer recommendations for evaluating and managing lung nodules detected...
2.
Holton S, Mitchem M, Chalian H, Pipavath S, Morrell E, Bhatraju P, et al.
PLoS One
. 2024 Aug;
19(8):e0285638.
PMID: 39106254
Acute respiratory distress syndrome (ARDS) has a fibroproliferative phase that may be followed by pulmonary fibrosis. Pulmonary fibrosis following COVID-19 pneumonia has been described at autopsy and following lung transplantation....
3.
Morrell E, Holton S, Wiedeman A, Kosamo S, Mitchem M, Dmyterko V, et al.
Am J Respir Cell Mol Biol
. 2024 Jul;
71(5):534-545.
PMID: 38950166
The relationship between the PD-L1 (Programmed Death-Ligand 1)/PD-1 pathway, lung inflammation, and clinical outcomes in acute respiratory distress syndrome (ARDS) is poorly understood. We sought to determine whether PD-L1/PD-1 in...
4.
Balu N, Pipavath S
J Magn Reson Imaging
. 2023 Jun;
59(3):920-921.
PMID: 37285083
No abstract available.
5.
Holton S, Mitchem M, Pipavath S, Morrell E, Bhatraju P, Hamerman J, et al.
medRxiv
. 2023 May;
PMID: 37205332
Acute respiratory distress syndrome (ARDS) has a fibroproliferative phase that may be followed by pulmonary fibrosis. This has been described in patients with COVID-19 pneumonia, but the underlying mechanisms have...
6.
Datta B, Prakash A, Yaddanapudi K, Ahlawat K, Tripathy J, Goyal P, et al.
Respir Med
. 2023 May;
213:107261.
PMID: 37127203
No abstract available.
7.
Wood D, Kazerooni E, Aberle D, Berman A, Brown L, Eapen G, et al.
J Natl Compr Canc Netw
. 2022 Jul;
20(7):754-764.
PMID: 35830884
The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening....
8.
Wu W, Bhatraju P, Cobb N, Sathe N, Duan K, Seitz K, et al.
Curr Probl Diagn Radiol
. 2022 May;
51(6):884-891.
PMID: 35610068
Purpose: To describe evolution and severity of radiographic findings and assess association with disease severity and outcomes in critically ill COVID-19 patients. Materials And Methods: This retrospective study included 62...
9.
Morrell E, Bhatraju P, Sathe N, Lawson J, Mabrey L, Holton S, et al.
Am J Physiol Lung Cell Mol Physiol
. 2022 May;
323(1):L14-L26.
PMID: 35608267
Critically ill patients manifest many of the same immune features seen in coronavirus disease 2019 (COVID-19), including both "cytokine storm" and "immune suppression." However, direct comparisons of molecular and cellular...
10.
Durfey S, Pipavath S, Li A, Vo A, Ratjen A, Carter S, et al.
mBio
. 2021 Dec;
12(6):e0314821.
PMID: 34903059
Drugs called CFTR modulators improve the physiologic defect underlying cystic fibrosis (CF) and alleviate many disease manifestations. However, studies to date indicate that chronic lung infections that are responsible for...